Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Tapolca – page 2

245 clinical trials in Tapolca, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tapolca at a glance
245
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

245 trials in Tapolca

Open in trial search

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:Astrazeneca AB

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:Astrazeneca AB

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Tapolca

What the registry says about research in the country

01 Respiratory Medicine

Innovative clinical research focusing on Chronic Obstructive Pulmonary Disease (COPD) management through advanced combination therapy approaches. The studies aim to evaluate new treatment options for improving cardiopulmonary outcomes in patients.

  • Triple Therapy Evaluation
  • Cardiopulmonary Outcomes
  • Bronchodilator Treatment

The research examines the comparative effectiveness of combination therapies including budesonide, glycopyrronium, and formoterol in treating COPD, with special attention to severe cardiopulmonary manifestations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.